Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
"NTRK fusion-positive tumors represent a significant therapeutic challenge, particularly in the setting of acquired resistance to existing TRK tyrosine kinase inhibitors (TKIs)," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "There are no approved treatments for NTRK-positive cancers for both TKI-naïve and TKI-pretreated patients in China. Repotrectinib has the potential to become a next-generation TKI that can be used across a broad range of NTRK fusion-positive solid tumors in both settings."
In February 2025, China's NMPA granted priority review to repotrectinib for the treatment of adult patients with advanced solid tumors that have an NTRK gene fusion.
About Repotrectinib
Repotrectinib is a next-generation tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers. Patients with solid tumors, including NSCLC, harboring ROS1 and NTRK gene fusions treated with approved targeted therapies often develop resistance mutations that limit binding of these drugs to their target. Ultimately, this leads to shortened duration of response and tumor progression. Repotrectinib is the first next-generation ROS1 and TRK TKI uniquely designed to improve durability of benefit, including in the brain, and to address acquired resistance.
In June 2024, AUGTYRO (repotrectinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.
In May 2024, AUGTYRO was approved by the NMPA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). It was approved by the FDA for this indication in November 2023.
Zai Lab has an exclusive license agreement with Turning Point Therapeutics, Inc. (a Bristol Myers Squibb company) to develop and commercialize AUGTYRO in Greater China (mainland China, Hong Kong, Taiwan, and Macau, collectively).
About NTRK-Positive Solid Tumors
NTRK-positive advanced malignancies are life-threatening with poor prognoses and represent an area of significant unmet medical need in adult and pediatric patients. Existing targeted therapies have demonstrated clinical benefits but are limited by the duration of response due to the emergence of acquired resistance mutations.1 In China, there was no approved treatment option for NTRK-positive cancers that was studied in both TKI-naïve and TKI-pretreated patients across solid tumors.
1 Harada G, Santini FC, Wilhelm C, Drilon A, et al. NTRK fusions in lung cancer: From biology to therapy. Lung Cancer. 2021;161:108-113.
About Zai Lab
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at https://x.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements relating to our prospects and plans for developing and commercializing repotrectinib in Greater China, the potential benefits of repotrectinib, and the potential treatment of NTRK-positive solid tumors. These forward-looking statements may contain words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business decisions, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Our SEC filings can be found on our website at www.zailaboratory.com and the SEC's website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421607809/en/
Contacts
For more information, please contact:Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 6943christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 5011shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
Finward Bancorp Announces Dividend
MUNSTER, Ind.--(BUSINESS WIRE)--Finward Bancorp (Nasdaq: FNWD) (the 'Bancorp' or 'Finward'), the holding company for Peoples Bank (the 'Bank'), today announced that on August 15, 2025 the Board of Directors of Finward declared a dividend of $0.12 per share on Finward's common stock payable on September 12, 2025 to shareholders of record at the close of business on August 29, 2025. Bancorp Finward Bancorp is a locally managed and independent financial holding company headquartered in Munster, Indiana, whose activities are primarily limited to holding the stock of Peoples Bank. Peoples Bank provides a wide range of personal, business, electronic and wealth management financial services from its 26 locations in Lake and Porter Counties in Northwest Indiana and the Chicagoland area. Finward Bancorp's common stock is quoted on The NASDAQ Stock Market, LLC under the symbol FNWD. The website provides information on Peoples Bank's products and services, and Finward Bancorp's investor relations. Forward Looking Statements This Current Report on Form 8-K may contain forward-looking statements regarding the financial performance, business prospects, growth, and operating strategies of Finward. For these statements, Finward claims the protections of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Statements in this communication should be considered in conjunction with the other information available about Finward, including the information in the filings Finward makes with the Securities and Exchange Commission ('SEC'). Forward-looking statements provide current expectations or forecasts of future events and are not guarantees of future performance. The forward-looking statements are based on management's expectations and are subject to a number of risks and uncertainties. Forward-looking statements are typically identified by using words such as 'anticipate,' 'estimate,' 'project,' 'intend,' 'plan,' 'believe,' 'will' and similar expressions in connection with any discussion of future operating or financial performance. Although management believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ materially from those expressed or implied in such statements. Risks and uncertainties that could cause actual results to differ materially include: the Bank's ability to demonstrate compliance with the terms of the previously disclosed memorandum of understanding entered into between the Bank and the Federal Deposit Insurance Corporation ('FDIC') and Indiana Department of Financial Institutions ('DFI'), or to demonstrate compliance to the satisfaction of the FDIC and/or DFI within prescribed time frames; the Bank's agreement under the memorandum of understanding to refrain from paying cash dividends without prior regulatory approval; changes in asset quality and credit risk; the inability to sustain revenue and earnings growth; changes in interest rates and capital markets; inflation; customer acceptance of Finward's products and services; customer borrowing, repayment, investment, and deposit practices; customer disintermediation; the introduction, withdrawal, success, and timing of business initiatives; competitive conditions; the inability to realize cost savings or revenues or to implement integration plans and other consequences associated with mergers, acquisitions, and divestitures; economic conditions; and the impact, extent, and timing of technological changes, capital management activities, and other actions of the Federal Reserve Board and legislative and regulatory actions and reforms. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in Finward's reports (such as the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K) filed with the SEC and available at the SEC's Internet website ( All subsequent written and oral forward-looking statements concerning Finward or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Except as required by law, Finward does not undertake any obligation to update any forward-looking statement to reflect circumstances or events that occur after the date the forward-looking statement is made. In addition to the above factors, we also caution that the actual amounts and timing of any future common stock dividends or share repurchases will be subject to various factors, including our capital position, financial performance, capital impacts of strategic initiatives, market conditions, and regulatory and accounting considerations, as well as any other factors that our Board of Directors deems relevant in making such a determination. Therefore, there can be no assurance that we will repurchase shares or pay any dividends to the holders of our common stock, or as to the amount of any such repurchases or dividends.
Business Wire
15 minutes ago
- Business Wire
NUTX Investors Have Opportunity to Join Nutex Health Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nutex Health Inc. ('Nutex' or 'the Company') (NASDAQ: NUTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nutex is the subject of a report published by Blue Orca Capital on July 22, 2025. The report claimed that the Company's share price 'surged' after it 'began submitting the majority of its patient bills to the arbitration process for settling out-of-network medical bills . . . using an unidentified 'third party IDR vendor.'' The report alleges that this 'mystery consultant' engaged in improper or illegal activities 'on behalf of and in conjunction with its healthcare billing clients.' Based on this report, shares of Nutex fell by 10.1% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CNBC
16 minutes ago
- CNBC
Tech IPOs are roaring after 'years of Prohibition' — it may be too good
The Bullish IPO this week took on added significance, perhaps because of the company name. When shares of the Peter Thiel-backed cryptocurrency exchange more than doubled out of the gate on Wednesday before finishing the day up 84%, it was the latest sign that the tech IPO bulls are back in business. In July, design software vendor Figma more than tripled in its New York Stock Exchange debut, and a month earlier shares of crypto firm Circle soared 168% in their first day on the Big Board. Wall Street has been waiting a long time for this. Three years ago, steep inflation and soaring interest effectively closed the market for public offerings. Tech stocks tanked and private capital dried up, forcing cash-burning startups to turn their attention away from growth and toward efficiency and profitability. The roadblock appeared to be loosening earlier this year, when companies like StubHub and Klarna filed their prospectuses, but then President Donald Trump roiled the markets in April with his plans for sweeping tariffs. Roadshows were put on indefinite hold. The president's tariff agenda has since stabilized a bit, and investor money is pouring into tech, pushing the Nasdaq to record levels, up more than 40% from this year's low in April. Optimism is growing that the hefty backlog of high-valued startups will continue to clear as CEOs and venture capitalists gain confidence that the public markets will welcome their top-tier companies. Ahead of Figma's debut, NYSE president Lynn Martin told CNBC's "Squawk on the Street" that immense demand for that offering could "open the floodgates" for the rest of the market. And earlier this week, Nasdaq CEO Adena Friedman told "Fast Money" that there's a "very healthy list" of companies looking to IPO in the second half of this year, ahead of the holiday season. "I've been meeting a lot of CEOs, getting them prepared to think about what they want in the public markets and where they're going," Friedman said. There are more than two-dozen venture-backed U.S. tech companies valued at $10 billion or more, according to CB Insights. StubHub has updated its prospectus, suggesting an offering is coming soon. "The IPO window is open," said Rick Heitzmann, a partner at venture firm FirstMark, in an interview with CNBC's "Closing Bell" this week. "You've seen across industry, broad-based support for IPOs, and therefore, we're advising companies we're investing in to get ready and go public." Another big topic among VCs and bankers is the regulatory environment. The Biden administration took heat from startup investors for cracking down on big acquisitions, mostly attributable to Lina Khan's perceived heavy hand at the Federal Trade Commission, while also failing to ease restrictions that they say make it less appealing for companies to go public than to stay private. Paul Atkins, the new head of the SEC, said in July he wants to "make IPOs great again," by removing some of the impediments around the complexity of disclosures and litigation risk. He hasn't offered many specific recommendations. Friedman told CNBC that the first conversation she had with Atkins after he took the job was about making it easier and more attractive for companies to go public. "The conversation was constructive along many fronts, looking at disclosure requirements, the proxy process, other things that really make it harder for companies to be public and navigate the public markets," Friedman said. "He's as interested as we are, so hopefully we'll turn that into great action." In addition to the big gains notched by Bullish, Figma and Circle, the public markets welcomed online banking provider Chime with a 37% gain last month and trading app eToro with a 29% pop in May. The health-tech market has seen two IPOs: Hinge Health and Omada Health. But it was the roaring debuts of Circle and Figma that sparked chatter of a new bull market for IPOs. Figma jumped 250% on IPO day after pricing shares a dollar ahead of an updated range. Circle's value more than doubled after the stablecoin issuer also priced above the expected range. That sort of price action reignited a debate ahead of the last IPO boom in 2020 and 2021, when venture capitalist Bill Gurley made the case that big first-day pops suggest intentionally mispriced offerings that hurt the company and hand easy money to new investors. Gurley has advocated for direct listings, where companies list shares at a price that effectively matches demand. As Figma was hitting the market, Gurley was back at it, referring to the big gains as an "expected & fully intentional" outcome benefitting clients of major investment banks "They bought it at $33 last night and can sell it today for over $90," he wrote. In a follow-up post, he said, "I would have loved to see DLs replace IPOs — it just makes sense to match supply/demand. But Wall Street may just be too addicted to the massive customer give-aways." Lise Buyer, founder of IPO advisory firm Class V Group, wrote on LinkedIn that the company gets to make the call on where it prices the stock and that plenty of thought gets put into the process. Also, in the IPO, companies are selling only a small percentage of outstanding shares — in Figma's case roughly 7% — so if they deliver on results, "there will very likely be plenty of future opportunities to sell more shares at higher prices." That's already happening. Circle said this week that it's offering another 10 million shares in a secondary offering. And on Friday's, CNBC's Leslie Picker reported that bankers for CoreWeave, which is up 150% since its March IPO, orchestrated some block trades this week. But Buyer warns that tech markets have a history of overheating. While there's always a difference between what institutions are willing to pay in an IPO and what exuberant retail investors will pay, it's currently "a gap like we haven't really seen since 1999, 2000," Buyer told CNBC, adding "and, of course, we know how that ended." Compared to the dot-com bubble, businesses that are going public now have sizable revenue and actual fundamentals, but that doesn't mean the IPO pops are sustainable, she said. "It's almost like we had several years of Prohibition," Buyer said, referring to a period a century ago when alcohol was banned in the U.S. "Folks, in some cases, are drinking to excess in the IPO market."
